Home LiteratureArticle Details
PMID: 7511176 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Journal of virology ·Vol. 68 ·No. 4 ·1994-04-00 ·Pages 2624-31

Javaherian K, Langlois AJ, Montefiori DC, Kent KA, Ryan KA, Wyman PD, Stott J, Bolognesi DP, Murphey-Corb M, Larosa GJ

Abstract

It has been shown previously that the major neutralizing epitopes in simian immunodeficiency virus (SIV) are discontinuous and conformation dependent and that the V3 loop, in contrast to that of human immunodeficiency virus (HIV) type 1, does not by itself elicit neutralizing antibodies (K. Javaherian et al., Proc. Natl. Acad. Sci. USA 89:1418-1422, 1992). We now present data showing that on the basis of fractionation of infected macaque sera, protease digestion of the envelope, and binding properties of two neutralizing monoclonal antibodies to SIV and SIV-HIV chimeric envelope proteins, changes in V3 can disrupt the conformation-dependent neutralization region. The chimeric protein did not produce significant neutralizing antibodies against either SIV or HIV. We also report that neutralizing antibodies elicited by recombinant SIV envelope proteins of mac251 and B670 isolates cross-neutralize. Finally, we show that deglycosylation of the SIV envelope results in a molecule which binds neither soluble CD4 nor the neutralizing monoclonal antibodies being investigated here and does not elicit sera with a significant neutralizing titer.

MeSH Terms
Acids/pharmacology Amino Acid Sequence Animals Antibodies, Monoclonal/immunology Antibodies, Viral/immunology Antigens, Viral/immunology CD4 Antigens/metabolism Cross Reactions Epitopes/immunology Glycosylation Guinea Pigs HIV Envelope Protein gp120/genetics,immunology Macaca Molecular Sequence Data Neutralization Tests Peptide Fragments/immunology Protein Binding Protein Conformation Protein Processing, Post-Translational Recombinant Fusion Proteins/immunology Retroviridae Proteins/genetics,immunology Simian Immunodeficiency Virus/immunology Viral Envelope Proteins/genetics,immunology
Chemicals
Acids Antibodies, Monoclonal Antibodies, Viral Antigens, Viral CD4 Antigens Epitopes HIV Envelope Protein gp120 Peptide Fragments Recombinant Fusion Proteins Retroviridae Proteins SIV envelope protein gp110 Viral Envelope Proteins
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Javaherian K
Repligen Corporation, Cambridge, Massachusetts 02139.
Langlois A J
Montefiori D C
Kent K A
Ryan K A
Wyman P D
Stott J
Bolognesi D P
Murphey-Corb M
Larosa G J
References (42)
42 references, click to expand
  1. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160.
    Science. 1989 Oct 6;246(4926):118-21 PMID: 2789433
  2. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  4. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.
    J Virol. 1990 Jul;64(7):3492-9 PMID: 2191152
  5. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.
    J Virol. 1990 Dec;64(12):5701-7 PMID: 2243375
  6. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.
    J Virol. 1991 Jan;65(1):190-4 PMID: 1985197
  7. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.
    Nature. 1991 Jan 10;349(6305):167-9 PMID: 1986308
  8. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
    Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542-6 PMID: 1988952
  9. Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.
    Virology. 1991 Feb;180(2):853-6 PMID: 1989393
  10. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.
    J Virol. 1991 Apr;65(4):1843-54 PMID: 2002545
  11. Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2.
    J Gen Virol. 1991 Jun;72 ( Pt 6):1261-7 PMID: 1710645
  12. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
    Science. 1991 Jul 5;253(5015):71-4 PMID: 1905842
  13. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
    Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6082-6 PMID: 2068087
  14. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.
    AIDS. 1991 Jul;5(7):829-36 PMID: 1716442
  15. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
    J Virol. 1991 Nov;65(11):6188-93 PMID: 1717717
  16. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  17. Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins.
    AIDS Res Hum Retroviruses. 1991 Jun;7(6):495-9 PMID: 1931228
  18. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS.
    J Virol. 1991 Dec;65(12):7025-31 PMID: 1942255
  19. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.
    J Virol. 1992 Jan;66(1):524-33 PMID: 1727497
  20. Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells.
    Virology. 1992 Jan;186(1):313-7 PMID: 1727607
  21. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells.
    AIDS Res Hum Retroviruses. 1991 Nov;7(11):889-98 PMID: 1760229
  22. Identification of B-cell antigenic sites on HIV-2 gp125.
    J Acquir Immune Defic Syndr. 1992;5(2):177-87 PMID: 1370692
  23. Population sequence analysis of a simian immunodeficiency virus (32H reisolate of SIVmac251): a virus stock used for international vaccine studies.
    AIDS Res Hum Retroviruses. 1992 Jan;8(1):77-88 PMID: 1736942
  24. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Nature. 1992 Feb 20;355(6362):728-30 PMID: 1741059
  25. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418-22 PMID: 1371358
  26. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
    J Virol. 1992 Apr;66(4):1875-83 PMID: 1548744
  27. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
    Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2175-9 PMID: 1549578
  28. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    J Virol. 1992 Jun;66(6):3602-8 PMID: 1374810
  29. B-cell epitope mapping of the entire SIVagm envelope glycoprotein including fine mapping of immunogenic regions.
    J Acquir Immune Defic Syndr. 1992;5(6):583-90 PMID: 1375290
  30. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147-51 PMID: 1380261
  31. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    J Virol. 1992 Dec;66(12):6997-7004 PMID: 1279195
  32. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    AIDS Res Hum Retroviruses. 1992 Sep;8(9):1611-8 PMID: 1457207
  33. Pathogenesis of human immunodeficiency virus infection.
    Microbiol Rev. 1993 Mar;57(1):183-289 PMID: 8464405
  34. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  35. Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry.
    Virology. 1993 Jul;195(1):167-74 PMID: 8317093
  36. SIV vaccines, 1991--a year in review.
    AIDS. 1991;5 Suppl 2:S115-27 PMID: 1845043
  37. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys.
    Nature. 1986 May 22-28;321(6068):435-7 PMID: 3012358
  38. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses.
    Nature. 1987 Aug 6-12;328(6130):539-43 PMID: 3497350
  39. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  40. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.
    J Virol. 1988 Oct;62(10):3695-702 PMID: 2458487
  41. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
    J Virol. 1988 Nov;62(11):4195-200 PMID: 2845130
  42. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).
    AIDS Res Hum Retroviruses. 1989 Oct;5(5):525-33 PMID: 2590556
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1994-04-00
Pages
2624-31
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC236740
Subset
IM
Grants
PHS HHS · UO1 A 128243-03 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com